NASDAQ · RAPP
Healthcare · Biotechnology
$30.86
Down-$0.29 (-0.93%)
Updated Oct 8, 2026, 12:02 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RAPP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
RAPP closed at $30.86 after 21 trading sessions, down 29.68% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $30.81 | $31.35 | $30.455 | $30.86 | 314.99K |
| Oct 6, 2026 | $32.92 | $34.00 | $30.01 | $31.15 | 235.74K |
| Oct 5, 2026 | $32.22 | $32.705 | $31.53 | $32.19 | 198.87K |
| Oct 2, 2026 | $33.33 | $34.48 | $31.77 | $32.17 | 277.63K |
| Oct 1, 2026 | $33.52 | $34.315 | $32.80 | $32.83 | 326.78K |
| Sep 30, 2026 | $33.17 | $34.05 | $32.62 | $33.60 | 582.03K |
| Sep 29, 2026 | $33.25 | $33.66 | $32.12 | $33.02 | 626.15K |
| Sep 28, 2026 | $33.48 | $33.995 | $32.36 | $33.44 | 552.31K |
| Sep 25, 2026 | $33.80 | $34.89 | $33.0502 | $33.91 | 711.81K |
| Sep 24, 2026 | $34.15 | $34.21 | $31.58 | $33.83 | 848.74K |
| Sep 23, 2026 | $41.01 | $41.47 | $33.38 | $34.13 | 745.55K |
| Sep 22, 2026 | $39.97 | $41.55 | $37.94 | $41.47 | 900.21K |
| Sep 21, 2026 | $40.70 | $42.18 | $39.11 | $39.66 | 616.98K |
| Sep 18, 2026 | $41.89 | $43.00 | $40.285 | $40.45 | 998.06K |
| Sep 17, 2026 | $42.13 | $42.90 | $41.39 | $41.95 | 397.3K |
| Sep 16, 2026 | $42.82 | $43.67 | $41.23 | $41.39 | 387.03K |
| Sep 15, 2026 | $43.87 | $43.98 | $41.76 | $42.68 | 189.31K |
| Sep 14, 2026 | $44.30 | $44.90 | $43.36 | $44.00 | 196.93K |
| Sep 11, 2026 | $44.21 | $44.30 | $43.01 | $43.62 | 251.79K |
| Sep 10, 2026 | $43.35 | $43.995 | $42.65 | $43.46 | 319.26K |
| Sep 9, 2026 | $45.17 | $45.42 | $43.13 | $43.885 | 437.74K |
The latest Smart Investors Daily articles mentioning RAPP.
Company
Market Activity
Research & News
RAPP research
Company profile and research snapshot.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Guggenheim | Buy | — |
| Sep 16, 2026 | BTIG | Buy | — |
| Aug 19, 2026 | BTIG | Buy | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | BTIG | Buy | — |
Generated Oct 7, 2026, 9:14 PM
Rapport Therapeutics stock declined 0.93% today despite receiving a new buy rating and $65 price target from Guggenheim, suggesting the market may have already priced in positive sentiment or investors are taking profits. The disconnect between bullish analyst initiation and modest price weakness indicates mixed investor sentiment around the stock's near-term trajectory.
Bottom line: While Guggenheim's buy initiation and $65 price target provide a bullish framework for RAPP, today's modest decline suggests investors remain cautious about near-term catalysts and execution risks. Shareholders should monitor clinical development updates and track whether the stock can build on analyst support or faces headwinds from sector-wide concerns.
Benzinga · Oct 6, 2026
Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $65.
SeekingAlpha · Sep 24, 2026
RAPP stock fell after RAP-219 updates. See focal onset seizure efficacy, Phase 2 bipolar mania catalysts, risks and long-term upsideâread now.
SeekingAlpha · Sep 23, 2026
2026-09-23. The following slide deck was published by Rapport Therapeutics, Inc.
Yahoo · Sep 23, 2026
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RAPP.
